208.43
price down icon0.53%   -1.12
after-market After Hours: 208.00 -0.43 -0.21%
loading
Ascendis Pharma A S Adr stock is traded at $208.43, with a volume of 393.83K. It is down -0.53% in the last 24 hours and up +6.57% over the past month. Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
See More
Previous Close:
$209.55
Open:
$214.06
24h Volume:
393.83K
Relative Volume:
0.85
Market Cap:
$12.84B
Revenue:
$393.98M
Net Income/Loss:
$-367.45M
P/E Ratio:
-33.12
EPS:
-6.293
Net Cash Flow:
$-460.07M
1W Performance:
-1.14%
1M Performance:
+6.57%
6M Performance:
+38.04%
1Y Performance:
+61.74%
1-Day Range:
Value
$208.34
$214.06
1-Week Range:
Value
$206.40
$216.45
52-Week Range:
Value
$118.03
$216.45

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
Name
Ascendis Pharma A S Adr
Name
Phone
-
Name
Address
-
Name
Employee
1,017
Name
Twitter
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
ASND's Discussions on Twitter

Compare ASND with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ASND
Ascendis Pharma A S Adr
208.43 12.69B 393.98M -367.45M -460.07M -6.293
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-03-25 Resumed Morgan Stanley Overweight
May-05-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-16-25 Initiated RBC Capital Mkts Outperform
Jan-07-25 Initiated UBS Buy
Sep-05-24 Upgrade Oppenheimer Perform → Outperform
Jun-25-24 Upgrade TD Cowen Hold → Buy
May-31-24 Initiated Stifel Buy
Dec-20-23 Initiated Jefferies Buy
Jun-14-23 Resumed Credit Suisse Neutral
Apr-05-23 Downgrade Oppenheimer Outperform → Perform
Apr-04-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-03-23 Downgrade Credit Suisse Outperform → Neutral
Oct-20-22 Initiated Goldman Buy
Aug-30-22 Resumed Berenberg Buy
Mar-28-22 Resumed Wedbush Outperform
Mar-15-22 Upgrade BofA Securities Neutral → Buy
Mar-01-22 Initiated Citigroup Buy
Feb-14-22 Upgrade Oppenheimer Perform → Outperform
Jan-06-22 Initiated Cowen Market Perform
Dec-08-21 Initiated Wells Fargo Overweight
Oct-20-21 Downgrade BofA Securities Buy → Neutral
Mar-30-21 Downgrade Oppenheimer Outperform → Perform
Mar-11-21 Resumed Stifel Buy
Dec-17-20 Initiated Berenberg Buy
Sep-14-20 Resumed JP Morgan Overweight
Mar-20-20 Initiated Oppenheimer Outperform
Oct-11-19 Initiated Morgan Stanley Overweight
Mar-25-19 Initiated Evercore ISI Outperform
Jan-24-19 Initiated Cantor Fitzgerald Overweight
Jan-24-19 Upgrade Leerink Partners Mkt Perform → Outperform
Jun-26-18 Initiated Stifel Buy
Apr-02-18 Reiterated Leerink Partners Mkt Perform
May-11-17 Initiated JP Morgan Overweight
Mar-09-17 Downgrade Leerink Partners Outperform → Mkt Perform
Feb-09-17 Initiated Credit Suisse Outperform
Sep-26-16 Initiated Wedbush Outperform
View All

Ascendis Pharma A S Adr Stock (ASND) Latest News

pulisher
Oct 12, 2025

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 12, 2025
pulisher
Oct 03, 2025

Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm

Oct 03, 2025
pulisher
Aug 20, 2025

Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com

Aug 20, 2025
pulisher
Aug 11, 2025

Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl

Aug 11, 2025
pulisher
Aug 08, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 08, 2025
pulisher
Aug 08, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily

Aug 08, 2025
pulisher
Aug 07, 2025

Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com

Aug 07, 2025
pulisher
Aug 04, 2025

Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com

Aug 04, 2025
pulisher
Jul 31, 2025

Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily

Jul 31, 2025
pulisher
Jul 29, 2025

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail

Jul 29, 2025
pulisher
Jul 28, 2025

Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com

Jul 28, 2025
pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl

Jul 25, 2025
pulisher
Jul 14, 2025

Ascendis Pharma reports positive results from hypothyroid trial - MSN

Jul 14, 2025
pulisher
Jul 02, 2025

Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com

Jul 02, 2025
pulisher
Jun 30, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 30, 2025
pulisher
Jun 26, 2025

European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize

Jun 26, 2025
pulisher
Jun 10, 2025

Canaccord holds Ascendis Pharma stock at $84 target - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

BofA raises Ascendis Pharma stock target to $216 - Investing.com

Jun 09, 2025
pulisher
Jun 04, 2025

Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN

Jun 04, 2025
pulisher
Jun 03, 2025

Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl

Jun 03, 2025
pulisher
Jun 02, 2025

BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

European ADRs Climb With Biotech Stocks Leading The Charge - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com

Jun 02, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com

May 27, 2025
pulisher
May 25, 2025

Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India

May 25, 2025
pulisher
May 15, 2025

Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India

May 15, 2025
pulisher
May 14, 2025

Ascendis Pharma grants new employee warrants - Investing.com

May 14, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial - Investing.com

May 13, 2025
pulisher
May 12, 2025

Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 09, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 09, 2025
pulisher
May 08, 2025

In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX

May 08, 2025
pulisher
May 02, 2025

Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com

May 02, 2025
pulisher
May 02, 2025

Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 16, 2025

RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com

Apr 16, 2025
pulisher
Apr 15, 2025

Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl

Apr 15, 2025
pulisher
Apr 14, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 11, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 07, 2025

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView

Apr 07, 2025
pulisher
Mar 27, 2025

UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com

Mar 27, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 17, 2025

Rising Momentum: Is Ascendis Pharma a Hidden Gem? - StocksToTrade

Mar 17, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 12, 2025

Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com

Feb 12, 2025

Ascendis Pharma A S Adr Stock (ASND) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):